• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Genentech

Genentech

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. Genentech Announces Plans to Expand Hillsboro Facility

    Genentech Announces Plans to Expand Hillsboro Facility

  2. Research and Markets: Genentech /Roche's Lucentis (ranibizumab) Macular Edema and Macular Degeneration Drug Forecast and Market Analysis to 2023

    Research and Markets: Genentech /Roche's Lucentis (ranibizumab) Macular Edema and Macular Degeneration Drug Forecast and Market Analysis to 2023

  3. Research and Markets: Lampalizumab (Macular Edema and Macular Degeneration) - Forecast and Market Analysis to 2023: Anti-Factor D (Also Known as RG7417 by Roche and as FCFD4514S by Its Subsidiary, ...

    Research and Markets: Lampalizumab (Macular Edema and Macular Degeneration) - Forecast and Market Analysis to 2023: Anti-Factor D (Also Known as RG7417 by Roche and as FCFD4514S by Its Subsidiary, Genentech )

  4. Asahi Kasei Pharma Selects Evotec as Its Partner for Ion Channel Drug Discovery

    Asahi Kasei Pharma Selects Evotec as Its Partner for Ion Channel Drug Discovery

  5. Research and Markets: Avastin (Macular Edema and Macular Degeneration) - Forecast and Market Analysis to 2023

    Research and Markets: Avastin (Macular Edema and Macular Degeneration) - Forecast and Market Analysis to 2023

  6. Survey Results: Genentech ’s Decision to Change Distribution of Critical Cancer Drugs Raises Costs, Reduces Availability

    Survey Results: Genentech ’s Decision to Change Distribution of Critical Cancer Drugs Raises Costs, Reduces Availability

  7. Foundation Medicine Announces Proposed Changes to its Board of Directors in Connection with the Pending Roche Transaction

    Foundation Medicine Announces Proposed Changes to its Board of Directors in Connection with the Pending Roche Transaction

  8. Takeda Licenses Rights to Use ImmunoGen, Inc.’s Novel Antibody-Drug Conjugate Technology

    Takeda Licenses Rights to Use ImmunoGen, Inc.’s Novel Antibody-Drug Conjugate Technology

  9. Cerulean Reports Fourth Quarter 2014 Corporate Highlights and Financial Results

    Cerulean Reports Fourth Quarter 2014 Corporate Highlights and Financial Results

  10. TapImmune Appoints David Laskow-Pooley, CEO of London Pharma, to its Board of Directors

    TapImmune Appoints David Laskow-Pooley, CEO of London Pharma, to its Board of Directors

1234
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.